BD announces a trial using the BD Libertas wearable injector for subcutaneous delivery of biologics. The decision to use the injector in this trial follows positive results from over 50 pre-clinical and clinical studies conducted by BD. The trial highlights the performance of the device, with subjects indicating willingness to use it if prescribed. BD's Pharmaceutical Systems president emphasizes the company's commitment to advancing large-volume injection science, ensuring therapies are accessible and patient-friendly. The BD Libertas system supports high-viscosity biologics delivery up to 50 centipoise and includes a transparent window for monitoring drug delivery, a push-button activation mechanism, and a color-coded status indicator. The company is currently validating fill-finish and final assembly processes with contract manufacturing organizations to support pharmaceutical collaborators from development to commercial-scale production. The device component is not subject to FDA 510(k) clearance or EU CE mark certification, allowing for faster commercialization. The trial demonstrates BD's innovative leadership in drug delivery technology.

BD announces wearable injector trial for subcutaneous delivery of biologics

BD announced a trial using the BD Libertas wearable injector for subcutaneous delivery of biologics, following positive results from over 50 pre-clinical and clinical studies. The device features a transparent window, push-button activation, and color-coded status indicators, and is not subject to FDA 510(k) or EU CE mark certification, enabling faster commercialization. BD is validating fill-finish processes with contract manufacturers to support pharmaceutical collaborators.